Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells
详细信息 查看全文
- 作者：Jung-Hyun Kim ; Minjung Song ; Geun-Ho Kang ; Eung-Ryoung Lee ; Hye-Yeon Choi ; Chung Lee ; Jin-Hoi Kim ; Youngsoo Kim ; Bon-Nyeo Koo ; Ssang-Goo Cho
- 关键词：Chronic myelogenous leukemia (CML) ; Flavonoid ; 3-Hydroxyflavone ; Imatinib mesylate-resistant cells ; Phosphor-Bcr/Abl ; Apoptosis
- 刊名：Leukemia Research
- 出版年：2012
- 出版时间：September, 2012
- 年：2012
- 卷：36
- 期：9
- 页码：1157-1164
- 全文大小：1092 K
文摘
Imatinib mesylate, a Bcr/Abl tyrosine kinase inhibitor, is widely used in treating chronic myeloid leukemia. However, drug-resistance of leukemia cells becomes an emergent problem. Herein, various flavonoids were screened for applicability in leukemia treatment, and 3-hydroxyflavone (3-HF) was found to be most effective in reducing cancer cell viability. The combination of 3-HF and imatinib mesylate resulted in significant apoptotic cell death in imatinib mesylate-resistant leukemia cells. Combined treatment resulted in apparent activation of caspases and decrease of the oncoprotein phosphor-Bcr/Abl in leukemia cells. Our results suggest that this combined treatment is beneficial in imatinib mesylate-resistant chronic myelogenous leukemia.